Global Physical Antidotes Market Research Report 2024

Publication ID:

PB505252693

Publication Date:

May 10, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Antidote is agent that counters the effects of poison or over dosage by another drug. It helps in neutralizing the dangerous effects of a poison in body and has scientific approaches that have been taken to assess the therapeutic value of antidotes.
The global Physical Antidotes market was valued at US$ 2033 million in 2023 and is anticipated to reach US$ 2528.7 million by 2030, witnessing a CAGR of 3.1% during the forecast period 2024-2030.
Global Antidote key players include Roche, Pfizer, Bayer, etc. Global top three manufacturers hold a share about 15%.
North America is the largest market, with a share about 35%, followed by Europe and China, both have a share about 50 percent.
In terms of product, Chemical Antidotes is the largest segment, with a share about 45%. And in terms of application, the largest application is Pesticide Poisoning, followed by Heavy Metal Poisoning.
This report aims to provide a comprehensive presentation of the global market for Physical Antidotes, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Physical Antidotes.
Report Scope
The Physical Antidotes market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Physical Antidotes market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Physical Antidotes manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Pfizer
Bayer
Johnson & Johnson
Novartis
Eli Lilly
Teva
Boehringer Ingelheim
Mylan
Fresenius Kabi
Baxter
Furen Pharmaceutical
GSK
Viatris
Segment by Type
Injection
Tablet
Others
Segment by Application
Pesticide Poisoning
Heavy Metal Poisoning
Animal Bites Poisoning
Cyanide Poisoning
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Physical Antidotes manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Physical Antidotes in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Physical Antidotes Market Overview
1.1 Product Overview and Scope of Physical Antidotes
1.2 Physical Antidotes Segment by Type
1.2.1 Global Physical Antidotes Market Value Comparison by Type (2024-2030)
1.2.2 Injection
1.2.3 Tablet
1.2.4 Others
1.3 Physical Antidotes Segment by Application
1.3.1 Global Physical Antidotes Market Value by Application: (2024-2030)
1.3.2 Pesticide Poisoning
1.3.3 Heavy Metal Poisoning
1.3.4 Animal Bites Poisoning
1.3.5 Cyanide Poisoning
1.3.6 Others
1.4 Global Physical Antidotes Market Size Estimates and Forecasts
1.4.1 Global Physical Antidotes Revenue 2019-2030
1.4.2 Global Physical Antidotes Sales 2019-2030
1.4.3 Global Physical Antidotes Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Physical Antidotes Market Competition by Manufacturers
2.1 Global Physical Antidotes Sales Market Share by Manufacturers (2019-2024)
2.2 Global Physical Antidotes Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Physical Antidotes Average Price by Manufacturers (2019-2024)
2.4 Global Physical Antidotes Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Physical Antidotes, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Physical Antidotes, Product Type & Application
2.7 Physical Antidotes Market Competitive Situation and Trends
2.7.1 Physical Antidotes Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Physical Antidotes Players Market Share by Revenue
2.7.3 Global Physical Antidotes Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Physical Antidotes Retrospective Market Scenario by Region
3.1 Global Physical Antidotes Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Physical Antidotes Global Physical Antidotes Sales by Region: 2019-2030
3.2.1 Global Physical Antidotes Sales by Region: 2019-2024
3.2.2 Global Physical Antidotes Sales by Region: 2025-2030
3.3 Global Physical Antidotes Global Physical Antidotes Revenue by Region: 2019-2030
3.3.1 Global Physical Antidotes Revenue by Region: 2019-2024
3.3.2 Global Physical Antidotes Revenue by Region: 2025-2030
3.4 North America Physical Antidotes Market Facts & Figures by Country
3.4.1 North America Physical Antidotes Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Physical Antidotes Sales by Country (2019-2030)
3.4.3 North America Physical Antidotes Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Physical Antidotes Market Facts & Figures by Country
3.5.1 Europe Physical Antidotes Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Physical Antidotes Sales by Country (2019-2030)
3.5.3 Europe Physical Antidotes Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Physical Antidotes Market Facts & Figures by Country
3.6.1 Asia Pacific Physical Antidotes Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Physical Antidotes Sales by Country (2019-2030)
3.6.3 Asia Pacific Physical Antidotes Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Physical Antidotes Market Facts & Figures by Country
3.7.1 Latin America Physical Antidotes Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Physical Antidotes Sales by Country (2019-2030)
3.7.3 Latin America Physical Antidotes Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Physical Antidotes Market Facts & Figures by Country
3.8.1 Middle East and Africa Physical Antidotes Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Physical Antidotes Sales by Country (2019-2030)
3.8.3 Middle East and Africa Physical Antidotes Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Physical Antidotes Sales by Type (2019-2030)
4.1.1 Global Physical Antidotes Sales by Type (2019-2024)
4.1.2 Global Physical Antidotes Sales by Type (2025-2030)
4.1.3 Global Physical Antidotes Sales Market Share by Type (2019-2030)
4.2 Global Physical Antidotes Revenue by Type (2019-2030)
4.2.1 Global Physical Antidotes Revenue by Type (2019-2024)
4.2.2 Global Physical Antidotes Revenue by Type (2025-2030)
4.2.3 Global Physical Antidotes Revenue Market Share by Type (2019-2030)
4.3 Global Physical Antidotes Price by Type (2019-2030)
5 Segment by Application
5.1 Global Physical Antidotes Sales by Application (2019-2030)
5.1.1 Global Physical Antidotes Sales by Application (2019-2024)
5.1.2 Global Physical Antidotes Sales by Application (2025-2030)
5.1.3 Global Physical Antidotes Sales Market Share by Application (2019-2030)
5.2 Global Physical Antidotes Revenue by Application (2019-2030)
5.2.1 Global Physical Antidotes Revenue by Application (2019-2024)
5.2.2 Global Physical Antidotes Revenue by Application (2025-2030)
5.2.3 Global Physical Antidotes Revenue Market Share by Application (2019-2030)
5.3 Global Physical Antidotes Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Physical Antidotes Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Physical Antidotes Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Physical Antidotes Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Physical Antidotes Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Bayer
6.3.1 Bayer Corporation Information
6.3.2 Bayer Description and Business Overview
6.3.3 Bayer Physical Antidotes Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Bayer Physical Antidotes Product Portfolio
6.3.5 Bayer Recent Developments/Updates
6.4 Johnson & Johnson
6.4.1 Johnson & Johnson Corporation Information
6.4.2 Johnson & Johnson Description and Business Overview
6.4.3 Johnson & Johnson Physical Antidotes Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Johnson & Johnson Physical Antidotes Product Portfolio
6.4.5 Johnson & Johnson Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Physical Antidotes Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis Physical Antidotes Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Physical Antidotes Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Eli Lilly Physical Antidotes Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Teva
6.6.1 Teva Corporation Information
6.6.2 Teva Description and Business Overview
6.6.3 Teva Physical Antidotes Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Teva Physical Antidotes Product Portfolio
6.7.5 Teva Recent Developments/Updates
6.8 Boehringer Ingelheim
6.8.1 Boehringer Ingelheim Corporation Information
6.8.2 Boehringer Ingelheim Description and Business Overview
6.8.3 Boehringer Ingelheim Physical Antidotes Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Boehringer Ingelheim Physical Antidotes Product Portfolio
6.8.5 Boehringer Ingelheim Recent Developments/Updates
6.9 Mylan
6.9.1 Mylan Corporation Information
6.9.2 Mylan Description and Business Overview
6.9.3 Mylan Physical Antidotes Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Mylan Physical Antidotes Product Portfolio
6.9.5 Mylan Recent Developments/Updates
6.10 Fresenius Kabi
6.10.1 Fresenius Kabi Corporation Information
6.10.2 Fresenius Kabi Description and Business Overview
6.10.3 Fresenius Kabi Physical Antidotes Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Fresenius Kabi Physical Antidotes Product Portfolio
6.10.5 Fresenius Kabi Recent Developments/Updates
6.11 Baxter
6.11.1 Baxter Corporation Information
6.11.2 Baxter Physical Antidotes Description and Business Overview
6.11.3 Baxter Physical Antidotes Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Baxter Physical Antidotes Product Portfolio
6.11.5 Baxter Recent Developments/Updates
6.12 Furen Pharmaceutical
6.12.1 Furen Pharmaceutical Corporation Information
6.12.2 Furen Pharmaceutical Physical Antidotes Description and Business Overview
6.12.3 Furen Pharmaceutical Physical Antidotes Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Furen Pharmaceutical Physical Antidotes Product Portfolio
6.12.5 Furen Pharmaceutical Recent Developments/Updates
6.13 GSK
6.13.1 GSK Corporation Information
6.13.2 GSK Physical Antidotes Description and Business Overview
6.13.3 GSK Physical Antidotes Sales, Revenue and Gross Margin (2019-2024)
6.13.4 GSK Physical Antidotes Product Portfolio
6.13.5 GSK Recent Developments/Updates
6.14 Viatris
6.14.1 Viatris Corporation Information
6.14.2 Viatris Physical Antidotes Description and Business Overview
6.14.3 Viatris Physical Antidotes Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Viatris Physical Antidotes Product Portfolio
6.14.5 Viatris Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Physical Antidotes Industry Chain Analysis
7.2 Physical Antidotes Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Physical Antidotes Production Mode & Process
7.4 Physical Antidotes Sales and Marketing
7.4.1 Physical Antidotes Sales Channels
7.4.2 Physical Antidotes Distributors
7.5 Physical Antidotes Customers
8 Physical Antidotes Market Dynamics
8.1 Physical Antidotes Industry Trends
8.2 Physical Antidotes Market Drivers
8.3 Physical Antidotes Market Challenges
8.4 Physical Antidotes Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Roche
Pfizer
Bayer
Johnson & Johnson
Novartis
Eli Lilly
Teva
Boehringer Ingelheim
Mylan
Fresenius Kabi
Baxter
Furen Pharmaceutical
GSK
Viatris

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂